



Australasian  
Dermatology  
Registry

# AUSTRALASIAN DERMATOLOGY REGISTRY AUTHORSHIP AND PUBLICATION POLICY

—

VERSION 1.0 APRIL 2023





## PURPOSE OF THE AUTHORSHIP AND PUBLICATION POLICY

The Australasian Dermatology Registry (ADR) encourages and facilitates analysis and publication of data to increase scientific knowledge pertaining to skin conditions including diagnosis, comorbidities, treatment, clinical outcomes, and quality of life of people with the relevant skin condition(s).

The purpose of this document is to set out the criteria for publishing Australasian Dermatology Registry data including confidentiality and privacy of participants and participating sites, authorship criteria, acknowledgement of contributing sites, and acknowledgement of funding source(s). This policy includes, but is not limited to, manuscripts, abstracts and presentations.

## THE AUSTRALASIAN DERMATOLOGY REGISTRY (ADR)

The ADR collects demographic, diagnosis, treatment, and quality of life data on people treated for skin conditions at participating sites within Australia and New Zealand. The registry is designed to improve the quality of care for people living with skin conditions by informing dermatologists of the efficacy and risks of current and emerging treatment, the risk factors for developing a skin condition, and the impact these conditions have on the quality of life of the patients.

## CONFIDENTIALITY AND PRIVACY OF PARTICIPANTS AND PARTICIPATING SITES

The data collected by the ADR are stored in a secure password protected database to protect against potential breaches of privacy (see [Data Security Policy](#) for additional information), with access only to authorised users.

All information stored within the registry is confidential, with access limited to core registry staff and sites where the participant has received treatment. De-identified data are available to researchers and clinicians from sites contributing data through the ADR data access policy with appropriate ethics and scientific advisory committee approval.

Publications and presentations can only include de-identified aggregate data for participants to maintain their privacy. No data that includes participant numbers of five or less will be published as this potentially has the risk of re-identification of participants.

Participating sites data must also be de-identified unless the principal investigator at the site approves the site to be identified and ethics approval to release the name of the site is approved (as the ADR ethics approval includes protecting the privacy of contributing sites).

## REVIEW OF PUBLICATION BEFORE SUBMISSION

All pre-publication drafts of publication/manuscript/abstract/poster utilising the ADR data are required to be reviewed and approved by the relevant scientific advisory committee prior to submission for publication. This is to ensure that any limitations in the data including scope of data collection, the quality of the data, or missing data are understood by the author and are included in the publication prior to submission. Manuscripts will also be reviewed to ensure privacy and confidentiality is maintained and that the participants, participating sites, and funding sources are acknowledged.



Manuscripts will be reviewed by at least two members of the scientific advisory committee and a response will be provided within two weeks.

## AUTHORSHIP GUIDELINES

The authorship guidelines for the ADR have been developed to comply with the “International Committee of Medical Journal Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations 2018)<sup>1</sup>” and the National Health and Medical Research Council Authorship Guidelines<sup>2</sup> from the Australian Code for the Responsible Conduct of Research.

This includes the following four criteria (from the ICMJE recommendations):

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and
- Drafting the work or revising it critically for important intellectual content; and
- Final approval of the version to be published; and
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The lead author is responsible for ensuring that all appropriate authors are included in the publication and no author who does not meet the above criteria is included. The lead author, in addition to identifying their role in the development of the publication, must be able to identify the role of all the authors.

## ACKNOWLEDGEMENT OF THE AUSTRALASIAN DERMATOLOGY REGISTRY

All publications utilising ADR data must acknowledge the registry, including registry patient participation, the contribution of the participating sites and funding sources.

We recommend any publications include:

“The authors of this publication would like to acknowledge the Australasian Dermatology Registry for providing the de-identified data used in the development of this publication, and to thank the registry participants who have contributed their data to the Australasian Dermatology Registry, the participating sites ([www.australasiadermatologyregistry.org.au/governance/participating-sites](http://www.australasiadermatologyregistry.org.au/governance/participating-sites)) and registry sponsors ([www.australasiadermatologyregistry.org.au/governance/sponsors-and-partners](http://www.australasiadermatologyregistry.org.au/governance/sponsors-and-partners)). We also appreciate the ADR staff, ADR scientific advisory committee (please name the committee) and the Skin Health Institute for their support relating to this project.”

The registry must also be acknowledged in the methodology section of the publication as the source of the data.

## AUSTRALASIAN DERMATOLOGY REGISTRY BIBLIOGRAPHY

The ADR Clinical Registry Coordinator will maintain a bibliography of publications and presentations utilising ADR data. This information will be shared with the ethics committees as part of the annual reporting, published on the ADR website, and included in the ADR newsletter.



To ensure the ADR publication and presentation lists are up to date please notify the registry at [registry@australasiadermatologyregistry.org.au](mailto:registry@australasiadermatologyregistry.org.au) of any accepted and published abstracts, presentations and manuscripts.

## REFERENCE

1. International Committee of Medical Journal Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals ([ICMJE Recommendations 2018](#))
2. Authorship: A guide supporting the Australian Code for the Responsible Conduct of Research. National Health and Medical Research Council, Australian Research Council and Universities Australia. Commonwealth of Australia, Canberra  
<https://www.nhmrc.gov.au/file/14358/download?token=jrA-2qrR>